Apogee Therapeutics (NASDAQ:APGE) Insider Sells $203,378.00 in Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 5,110 shares of the business’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $39.80, for a total transaction of $203,378.00. Following the transaction, the insider owned 284,733 shares of the company’s stock, valued at approximately $11,332,373.40. This represents a 1.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, September 3rd, Carl Dambkowski sold 2,725 shares of Apogee Therapeutics stock. The stock was sold at an average price of $37.87, for a total value of $103,195.75.
• On Wednesday, August 6th, Carl Dambkowski sold 2,725 shares of Apogee Therapeutics stock. The stock was sold at an average price of $37.78, for a total value of $102,950.50.

Apogee Therapeutics Price Performance

APGE opened at $39.88 on Friday. The business’s 50-day moving average price is $37.59 and its two-hundred day moving average price is $38.19. Apogee Therapeutics Inc. has a 1 year low of $26.20 and a 1 year high of $63.50. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of -9.66 and a beta of 1.43.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings results on Monday, August 11th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.10). Sell-side analysts anticipate that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Apogee Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. lifted its stake in Apogee Therapeutics by 57.8% during the second quarter. China Universal Asset Management Co. Ltd. now owns 14,248 shares of the company’s stock worth $619,000 after purchasing an additional 5,216 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Apogee Therapeutics by 754.7% during the second quarter. Tower Research Capital LLC TRC now owns 8,419 shares of the company’s stock worth $366,000 after purchasing an additional 7,434 shares during the last quarter. E Fund Management Co. Ltd. bought a new stake in Apogee Therapeutics during the second quarter worth $204,000. Sofinnova Investments Inc. bought a new stake in Apogee Therapeutics during the second quarter worth $3,308,000. Finally, Perceptive Advisors LLC lifted its stake in Apogee Therapeutics by 5.3% during the second quarter. Perceptive Advisors LLC now owns 1,182,148 shares of the company’s stock worth $51,341,000 after purchasing an additional 59,381 shares during the last quarter. 79.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Royal Bank Of Canada assumed coverage on Apogee Therapeutics in a research report on Thursday, September 25th. They set an “outperform” rating and a $60.00 price target on the stock. Zacks Research downgraded Apogee Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Apogee Therapeutics in a research report on Saturday, September 27th. Wedbush reissued an “outperform” rating and set a $90.00 price target on shares of Apogee Therapeutics in a research report on Monday, August 11th. Finally, Bank of America boosted their price objective on Apogee Therapeutics from $78.00 to $87.00 and gave the stock a “buy” rating in a report on Thursday, August 28th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $92.63.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.